Search
calaspargase pegol-mkn (Asparlas)
Indications:
- acute lymphoblastic leukemia (ALL) in children & young adults 1 month to 21 years
Dosage:
- 2,500 units/m2 IV every 21 days
Adverse effects:
- elevated serum transaminases, increased serum bilirubin
- pancreatitis
- abnormal clotting studies
Mechanism of action:
- maintenance of nadir serum asparaginase > 0.1 U/mL
General
antineoplastic agent (chemotherapeutic agent)
References
- The ASCO Post. 12/20/2018
FDA Approves Calaspargase Pegol-mknl for Pediatric and Young
Adult Patients With ALL.
https://www.ascopost.com/News/59598